Trial Profile
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess the Effects of SRT2104 Upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human Volunteers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs SRT 2104 (Primary)
- Indications Chronic obstructive pulmonary disease; Plaque psoriasis; Type 2 diabetes mellitus; Ulcerative colitis
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 27 Oct 2014 New trial record